Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study

Results of the randomized phase III study in recent-onset human type 1 diabetes

DEFEND Investigator Group

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)S72
JournalDiabetes Technology and Therapeutics
Volume18
DOIs
StatePublished - Feb 1 2016

Fingerprint

Type 1 Diabetes Mellitus
Monoclonal Antibodies
otelixizumab

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

@article{cc27ac5363c249cb88eaa340da7a2097,
title = "Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes",
author = "{DEFEND Investigator Group} and R. Aronson and Gottlieb, {P. A.} and Christiansen, {J. S.} and Donner, {Thomas W} and E. Bosi and Bode, {B. W.} and P. Pozzilli",
year = "2016",
month = "2",
day = "1",
doi = "10.1089/dia.2016.2507",
language = "English (US)",
volume = "18",
pages = "S72",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study

T2 - Results of the randomized phase III study in recent-onset human type 1 diabetes

AU - DEFEND Investigator Group

AU - Aronson, R.

AU - Gottlieb, P. A.

AU - Christiansen, J. S.

AU - Donner, Thomas W

AU - Bosi, E.

AU - Bode, B. W.

AU - Pozzilli, P.

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://www.scopus.com/inward/record.url?scp=84957670793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957670793&partnerID=8YFLogxK

U2 - 10.1089/dia.2016.2507

DO - 10.1089/dia.2016.2507

M3 - Article

VL - 18

SP - S72

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

ER -